Suppr超能文献

套细胞淋巴瘤中TP53突变状态与p53免疫组化数字定量之间的相关性

Correlation between TP53 mutational status and digital quantification of p53 immunohistochemistry in mantle cell lymphoma.

作者信息

Yan Mingfei, Sethi Shenon, Epstein-Peterson Zachary, Kumar Anita, Dogan Ahmet, Galera Pallavi

机构信息

Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Virchows Arch. 2025 Aug 25. doi: 10.1007/s00428-025-04227-x.

Abstract

TP53 mutation is a significant negative prognostic factor in mantle cell lymphoma (MCL). While p53 immunohistochemical (IHC) staining is frequently used to evaluate TP53 mutation status, specific cut-offs correlating with mutations remain undefined and largely empirical. This study analyzed tumor specimens from 172 patients with MCL with both p53 IHC and TP53 mutation data, categorizing p53 nuclear expression into four groups (0 + , 1 + , 2 + , and 3 +) using digital image analysis. We established IHC cut-offs with 100% specificity for identifying TP53 non-truncating mutations: 5% for 3 + nuclei, 50% for combined 2 + and 3 + nuclei, and an H-score of 150. The combined 2 + and 3 + nuclei percentage showed the highest sensitivity and negative predictive value. Notably, p53 IHC expression did not significantly correlate with the variant allele frequencies (VAFs) of TP53 missense mutations. However, patients with both TP53 missense and ATM mutations displayed lower p53 expression compared to those with only TP53 missense mutations. TP53 truncating mutations affecting the DNA-binding domain were associated with null p53 staining, while truncating mutations in the tetramerization domain showed weak to moderate staining. Cases with single nucleotide substitutions involving TP53 splice sites showed weak to moderate p53 staining and lacked 3 + nuclei. In cases where multiple types of TP53 mutations coexisted, the clonally dominant mutation influenced the overall p53 expression level. Finally, we observed significantly worse overall survival in patients demonstrating p53 overexpression by using the above mentioned IHC cut-offs. This study provides essential evidence for interpreting p53 IHC staining and may potentially guide rapid risk stratification of patients with MCL, especially in limited resource settings.

摘要

TP53突变是套细胞淋巴瘤(MCL)中一个重要的不良预后因素。虽然p53免疫组织化学(IHC)染色常用于评估TP53突变状态,但与突变相关的具体临界值仍未明确且大多基于经验。本研究分析了172例MCL患者的肿瘤标本,同时具备p53 IHC和TP53突变数据,采用数字图像分析将p53核表达分为四组(0 +、1 +、2 +和3 +)。我们建立了具有100%特异性的IHC临界值,用于识别TP53非截短突变:3 +核为5%,2 +和3 +核合并为50%,H评分为150。2 +和3 +核合并百分比显示出最高的敏感性和阴性预测值。值得注意的是,p53 IHC表达与TP53错义突变的变异等位基因频率(VAFs)无显著相关性。然而,与仅携带TP53错义突变的患者相比,同时携带TP53错义突变和ATM突变的患者p53表达较低。影响DNA结合域的TP53截短突变与p53染色缺失相关,而四聚化域的截短突变显示出弱至中度染色。涉及TP53剪接位点的单核苷酸替换病例显示出弱至中度p53染色且无3 +核。在多种类型TP53突变共存的病例中,克隆优势突变影响整体p53表达水平。最后,我们观察到使用上述IHC临界值显示p53过表达的患者总生存期显著更差。本研究为解释p53 IHC染色提供了重要证据,并可能潜在地指导MCL患者的快速风险分层,特别是在资源有限的情况下。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验